The quarter was broadly in line with the limited published earnings bar. SELLAS reported a $0.05 per-share loss, versus published Q2 estimates clustered around a $0.04–$0.05 loss, so the financial result was a meet rather than a beat. There is no revenue to assess because the company remains pre-commercial.
| Metric | Q2 2026 | Q2 2025 / comparison | Read |
|---|---|---|---|
| Research and development expense | $6.3M | $3.9M | Higher trial and BLA-preparation spending (Research and Development Expenses) |
| General and administrative expense | $4.4M | $3.0M | Higher professional fees and stock compensation (General and Administrative Expenses) |
| Net loss | $9.6M | $6.6M | Larger absolute loss (Net Loss) |
| Loss per share | $0.05 | $0.07 | Lower loss per share, helped by a much larger share count (Net Loss; Per share information) |
| Cash and cash equivalents | $138.3M | $71.8M at Dec. 31, 2025 | Significantly higher liquidity (Balance Sheet) |
| Shares outstanding | 201.9M | 153.1M at Dec. 31, 2025 | Approximately 32% increase, indicating material dilution (Balance Sheet) |
The operational update is progress, not a new de-risking event. The REGAL Phase 3 GPS study is nearing its prespecified 80th event, but the filing does not say that the event has occurred, provide efficacy data, or narrow the timing beyond the eventual database lock and topline disclosure (Phase 3 REGAL Trial of GPS). SLS009 has enrolled 28 of 80 patients, with topline data still expected in the fourth quarter of 2026 (Ongoing dosing of SLS009 in earlier-line AML). Those milestones maintain the existing narrative rather than materially changing the clinical-risk profile.
The stronger cash position comes with a meaningful cost to existing holders. Cash increased by $66.6 million from December 31, 2025, while issued and outstanding shares rose by 48.8 million; the filing does not identify the specific financing transaction in the supplied exhibit, so the exact source of the funding is unclear (Balance Sheet). The company has more resources to fund GPS and SLS009, but the per-share economics are spread across substantially more shares.
Spending is accelerating ahead of potential GPS commercialization work. First-half research and development expense rose to $11.4 million from $7.1 million, primarily because of manufacturing, clinical, and regulatory costs tied to preparing for a potential BLA (Research and Development Expenses). That supports execution toward a regulatory milestone, but it also means higher cash consumption before any clinical or regulatory validation is reported.
Net read: a mixed, largely status-quo quarter. The earnings line met expectations and liquidity improved, but the filing delivered no new clinical efficacy signal, no confirmed REGAL readout, and substantial share-count expansion. The picture is better funded and moving toward key catalysts, not materially less risky.
Read the original 8-K on SEC EDGAR ↗